Allergy Rhinitis | A Pipeline Analysis Report 2018 | Technavio

Technavio has published a new report on the drug development pipeline for allergy rhinitis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the allergy rhinitis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat allergy rhinitis.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Allergy rhinitis: Market overview

Allergy rhinitis is also known as hay fever. It is caused due to allergy response of the body to the certain type of allergens. Pollen is found to be one of the most common allergens in seasonal allergy rhinitis. Some external factors that can help to trigger or worsen the condition include cigarette smoke, chemicals, humidity, air pollution, and wind.

According to a senior analyst at Technavio for research on infectious and rare diseases, “Some of the complications that can arise from allergy rhinitis are the inability to sleep, frequent ear infection, and headaches, and development or worsening of the symptoms of asthma.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Allergy rhinitis: Segmentation analysis

This market research report segments the allergy rhinitis market based on therapies employed that includes monotherapy, combination therapy, and unknown, RoA (subcutaneous, intranasal, sublingual, intradermal, intravenous, and unknown), therapeutic modalities (biological, small molecules, vaccine, monoclonal antibody, and unknown), targets for drugs under development (immune system, immunoglobulin E, glucocorticoid receptor, other, and unknown), MoA (immunomodulator, IgE receptor antagonist, glucocorticoid receptor agonist, and others), drugs under development (discovery, pre-clinical, phase I, phase I/II, phase II, phase III, pre-registration, and unknown), and recruitment status (not yet recruiting, recruiting, active not recruiting, completed, unknown and NA). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company Overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline for allergy rhinitis, including a detailed study of the pipeline molecules.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com